Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Microbes Infect ; 25(6): 105122, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36842669

RESUMEN

Prior infections can provide protection or enhance susceptibility to a subsequent infection through microorganism's interaction or host immunomodulation. Staphylococcus aureus (SA) and Cryptococcus gattii (CG) cause lungs infection, but it is unclear how they interact in vivo. This study aimed to study the effects of the primary SA lung infection on secondary cryptococcosis caused by CG in a murine model. The mice's survival, fungal burden, behavior, immune cells, cytokines, and chemokines were quantified to evaluate murine cryptococcosis under the influence of a previous SA infection. Further, fungal-bacterial in vitro interaction was studied in a culture medium and a phagocytosis assay. The primary infection with SA protects animals from the subsequent CG infection by reducing lethality, improving behavior, and impairing the fungal proliferation within the host. This phenotype was associated with the proinflammatory antifungal host response elicited by the bacteria in the early stage of cryptococcosis. There was no direct inhibition of CG by SA, although the phagocytic activity of macrophages was reduced. Identifying mechanisms involved in this protection may lead to new approaches for preventing and treating cryptococcosis.


Asunto(s)
Criptococosis , Cryptococcus gattii , Cryptococcus neoformans , Animales , Ratones , Cryptococcus neoformans/genética , Staphylococcus aureus , Modelos Animales de Enfermedad , Criptococosis/microbiología , Criptococosis/prevención & control , Cryptococcus gattii/fisiología
2.
Contemp Clin Trials Commun ; 22: 100745, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33997457

RESUMEN

BACKGROUND: Cryptococcosis affects more than 220,000 patients/year, with high mortality even when the standard treatment [amphotericin B (AMB), 5-flucytosin (5-FC) and fluconazole] is used. AMB presents high toxicity and 5-FC is not currently available in Brazil. In a pre-clinical study, pioglitazone (PIO - an antidiabetic drug) decreased AMB toxicity and lead to an increased mice survival, reduced morbidity and fungal burden in brain and lungs. The aim of this trial is to evaluate the efficacy and safety of PIO combined with standard antifungal treatment for human cryptococcosis. METHODS: A phase 1/2, randomized, double blind, placebo-controlled trial will be performed with patients from Belo Horizonte, Brazil. They will be divided into three groups (placebo, PIO 15 mg/day or PIO 45 mg/day) and will receive an additional pill during the induction phase of cryptococcosis' treatment. Our hypothesis is that treated patients will have increased survival, so the primary outcome will be the mortality rate. Patients will be monitored for survival, side effects, fungal burden and inflammatory mediators in blood and cerebrospinal fluid. The follow up will occur for up 60 days. CONCLUSIONS: We expect that PIO will be an adequate adjuvant to the standard cryptococcosis' treatment. TRIAL REGISTRATION: ICTRP/WHO (and International Clinical Trial Registry Plataform (ICTRP/WHO) (http://apps.who.int/trialsearch/Trial2.aspx?TrialID=RBR-9fv3f4), RBR-9fv3f4 (http://www.ensaiosclinicos.gov.br/rg/RBR-9fv3f4). UTN Number: U1111-1226-1535. Ethical approvement number: CAAE 17377019.0.0000.5149.

3.
Sci Total Environ ; 740: 140135, 2020 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-32927573

RESUMEN

The increasing human population requires ongoing efforts in food production. This is frequently associated with an increased use of agrochemicals, leading to environmental contamination and altering microbial communities, including human fungal pathogens that reside in the environment. Cryptococcus gattii is an environmental yeast and is one of the etiological agents of cryptococcosis. Benomyl (BEN) is a broad-spectrum fungicide used on several crops. To study the effects of agrochemicals on fungal pathogens, we first evaluated the susceptibility of C. gattii to BEN and the interactions with clinical antifungals. Antagonistic interaction between BEN and fluconazole was seen and was strain- and concentration-dependent. We then induced BEN-resistance by culturing strains in increasing drug concentrations. One strain demonstrated to be more resistant and showed increased multidrug efflux pump gene (MDR1) expression and increased rhodamine 6G efflux, leading to cross-resistance between BEN and fluconazole. Morphologically, BEN-adapted cells had a reduced polysaccharide capsule; an increased surface/volume ratio; increased growth rate in vitro and inside macrophages and also higher ability in crossing an in vitro model of blood-brain-barrier. BEN-adapted strain demonstrated to be hypervirulent in mice, leading to severe symptoms of cryptococcosis, early mortality and higher fungal burden in the organs, particularly the brain. The parental strain was avirulent in murine model. In vivo cross-resistance between BEN and fluconazole was observed, with mice infected with the adapted strain unable to present any improvement in survival and behavior when treated with this antifungal. Furthermore, BEN-adapted cells cultured in drug-free media maintained the hypervirulent and cross-resistant phenotype, suggesting a persistent effect of BEN on C. gattii. In conclusion, exposure to BEN induces cross-resistance with fluconazole and increases the virulence of C. gattii. Altogether, our results indicate that agrochemicals may lead to unintended consequences on non-target species and this could result in severe healthy problems worldwide.


Asunto(s)
Cryptococcus gattii , Fungicidas Industriales/farmacología , Animales , Antifúngicos , Farmacorresistencia Fúngica , Humanos , Ratones , Pruebas de Sensibilidad Microbiana
4.
Med Mycol ; 58(6): 835-844, 2020 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-31919505

RESUMEN

Cryptococcosis is a life-threatening fungal infection, and its current treatment is toxic and subject to resistance. Drug repurposing represents an interesting approach to find drugs to reduce the toxicity of antifungals. In this study, we evaluated the combination of N-acetylcysteine (NAC) with amphotericin B (AMB) for the treatment of cryptococcosis. We examined the effects of NAC on fungal morphophysiology and on the macrophage fungicidal activity 3 and 24 hours post inoculation. The therapeutic effects of NAC combination with AMB were investigated in a murine model with daily treatments regimens. NAC alone reduced the oxidative burst generated by AMB in yeast cells, but did not inhibit fungal growth. The combination NAC + AMB decreased capsule size, zeta potential, superoxide dismutase activity and lipid peroxidation. In macrophage assays, NAC + AMB did not influence the phagocytosis, but induced fungal killing with different levels of oxidative bursts when compared to AMB alone: there was an increased reactive oxygen species (ROS) after 3 hours and reduced levels after 24 hours. By contrast, ROS remained elevated when AMB was tested alone, demonstrating that NAC reduced AMB oxidative effects without influencing its antifungal activity. Uninfected mice treated with NAC + AMB had lower concentrations of serum creatinine and glutamate-pyruvate transaminase in comparison to AMB. The combination of NAC + AMB was far better than AMB alone in increasing survival and reducing morbidity in murine-induced cryptococcosis, leading to reduced fungal burden in lungs and brain and also lower concentrations of pro-inflammatory cytokines in the lungs. In conclusion, NAC + AMB may represent an alternative adjuvant for the treatment of cryptococcosis.


Asunto(s)
Acetilcisteína/uso terapéutico , Anfotericina B/toxicidad , Antifúngicos/uso terapéutico , Criptococosis/tratamiento farmacológico , Ácido Desoxicólico/toxicidad , Riñón/efectos de los fármacos , Anfotericina B/farmacología , Anfotericina B/uso terapéutico , Animales , Antifúngicos/farmacología , Antifúngicos/toxicidad , Encéfalo/efectos de los fármacos , Encéfalo/microbiología , Creatinina/sangre , Criptococosis/microbiología , Cryptococcus/efectos de los fármacos , Ácido Desoxicólico/farmacología , Ácido Desoxicólico/uso terapéutico , Modelos Animales de Enfermedad , Combinación de Medicamentos , Reposicionamiento de Medicamentos , Femenino , Riñón/microbiología , Pulmón/efectos de los fármacos , Pulmón/microbiología , Macrófagos/efectos de los fármacos , Macrófagos/microbiología , Ratones , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Especies Reactivas de Oxígeno
5.
Med Mycol ; 58(1): 47-53, 2020 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-30888411

RESUMEN

The chemical control of pests and weeds is employed to improve crop production and the quality of agricultural products. The intensive use of pesticides, however, may cause environmental contamination, thus altering microbial communities. Cryptococcus gattii is an environmental yeast and the causative agent of cryptococcosis in both humans and animals. Up to this day, the effects of agrochemicals on human pathogens living in nature are still widely unknown. In this work, we analyzed the susceptibility of C. gattii to nonfungicide agrochemicals (herbicides and insecticides). Microdilution and drug-combination susceptibility tests were performed for the herbicides flumioxazin (FLX), glyphosate (GLY), isoxaflutole (ISO), pendimethalin (PEND), and also for the insecticide fipronil (FIP). Moreover, these compounds were combined with the clinical antifungals amphotericin B and fluconazole. The MIC values found for the agrochemicals were the following: < 16 µg/ml, for flumioxazin; 128 to 256 µg/ml, for FIP, ISO, and PEND; and >256 µg/ml, for GLY. Synergistic and antagonistic interactions, depending on the strain and concentration tested, were also observed. All strains had undergone adaptation to increasing levels of agrochemicals, in order to select the less susceptible subpopulations. During this process, one C. gattii strain (196 L/03) tolerated high concentrations (50 to 900 µg/ml) of all pesticides assessed. Subsequently, the strain adapted to flumioxazin, isoxaflutole and pendimethalin showed a reduction in the susceptibility to agrochemicals and clinical antifungals, suggesting the occurrence of cross-resistance. Our data point to the risk of exposing C. gattii to agrochemicals existing in the environment, once it might impact the susceptibility of clinical antifungals.


Asunto(s)
Agroquímicos/farmacología , Cryptococcus gattii/efectos de los fármacos , Farmacorresistencia Fúngica , Antifúngicos/farmacología , Cryptococcus gattii/patogenicidad , Combinación de Medicamentos , Herbicidas/farmacología , Insecticidas/farmacología , Pruebas de Sensibilidad Microbiana
6.
Int J Antimicrob Agents ; 54(3): 301-308, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31279153

RESUMEN

Approximately 180,000 people worldwide die from cryptococcosis each year, probably due to the ineffectiveness and toxicity of drugs currently available to treat the disease. Amphotericin B (AMB) is effective for killing the fungus, but has serious adverse effects linked to excessive production of reactive oxygen species which compromise renal function. Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-γ agonist widely repositioned as an adjuvant of various drugs that have toxic effects due to its antioxidant and anti-inflammatory effects. This study evaluated PIO in combination with AMB for the treatment of cryptococcosis. PIO was found to reduce serum creatinine and glutamic-oxalacetic transaminase levels in mice treated with PIO+AMB. In vitro, PIO was able to control harmful oxidative bursts induced by AMB without compromising the antifungal effect. In vivo, PIO+AMB increased the survival rate compared with AMB alone, and improved the morbidity of the animals. PIO+AMB was more efficient than AMB alone for inhibiting fungal transmigration from the lungs to the brain, and killing yeasts that reached the central nervous system, avoiding the establishment of meningoencephalitis. In a phagocytosis assay, PIO did not influence the engulfment and fungicidal activity of macrophages induced by AMB, but reduced the oxidative bursts after the reduction of fungal burden, pointing to control of the pathogen without leading to excessive stress which can be damaging to the host. In conclusion, PIO+AMB was found to ameliorate cryptococcosis in a murine model, indicating that it is a promising therapeutic adjuvant for combating and controlling this fungal infection.


Asunto(s)
Anfotericina B/administración & dosificación , Antifúngicos/administración & dosificación , Antioxidantes/administración & dosificación , Criptococosis/tratamiento farmacológico , Pioglitazona/administración & dosificación , Anfotericina B/farmacología , Animales , Antifúngicos/farmacología , Antioxidantes/farmacología , Criptococosis/patología , Cryptococcus gattii/efectos de los fármacos , Modelos Animales de Enfermedad , Reposicionamiento de Medicamentos , Quimioterapia Combinada/métodos , Ratones Endogámicos C57BL , Pioglitazona/farmacología , Análisis de Supervivencia , Resultado del Tratamiento
7.
Sci Rep ; 7(1): 4661, 2017 07 05.
Artículo en Inglés | MEDLINE | ID: mdl-28680034

RESUMEN

Cryptococcus spp., the causative agents of cryptococcosis, are responsible for deaths of hundreds of thousands of people every year worldwide. The drawbacks of available therapeutic options are aggravated by the increased resistance of yeast to the drugs, resulting in inefficient therapy. Also, the antifungal 5FC is not available in many countries. Therefore, a combination of antifungal drugs may be an interesting option, but in vitro and theoretical data point to the possible antagonism between the main antifungals used to treat cryptococcosis, i.e., fluconazole (FLC), and amphotericin B (AMB). Therefore, in vivo studies are necessary to test the above hypothesis. In this study, the efficacy of FLC and AMB at controlling C. gattii infection was evaluated in a murine model of cryptococcosis caused by C. gattii. The infected mice were treated with FLC + AMB combinations and showed a significant improvement in survival as well as reduced morbidity, reduced lung fungal burden, and the absence of yeast in the brain when FLC was used at higher doses, according to the Tukey test and principal component analysis. Altogether, these results indicate that combinatorial optimization of antifungal therapy can be an option for effective control of cryptococcosis.


Asunto(s)
Anfotericina B/administración & dosificación , Antifúngicos/administración & dosificación , Criptococosis/tratamiento farmacológico , Fluconazol/administración & dosificación , Anfotericina B/farmacología , Animales , Antifúngicos/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/microbiología , Cryptococcus gattii/efectos de los fármacos , Modelos Animales de Enfermedad , Quimioterapia Combinada , Fluconazol/farmacología , Humanos , Pulmón/efectos de los fármacos , Pulmón/microbiología , Ratones , Pruebas de Sensibilidad Microbiana , Resultado del Tratamiento
8.
Eur J Pharm Sci ; 92: 235-43, 2016 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-27235581

RESUMEN

The emergence of fluconazole-resistant Cryptococcus gattii is a global concern, since this azole is the main antifungal used worldwide to treat patients with cryptococcosis. Although pharmacokinetic (PK) and pharmacodynamic (PD) indices are useful predictive factors for therapeutic outcomes, there is a scarcity of data regarding PK/PD analysis of antifungals in cryptococcosis caused by resistant strains. In this study, PK/PD parameters were determined in a murine model of cryptococcosis caused by resistant C. gattii. We developed and validated a suitable liquid chromatography-electrospray ionization tandem mass spectrometry method for PK studies of fluconazole in the serum, lungs, and brain of uninfected mice. Mice were infected with susceptible or resistant C. gattii, and the effects of different doses of fluconazole on the pulmonary and central nervous system fungal burden were determined. The peak levels in the serum, lungs, and brain were achieved within 0.5h. The AUC/MIC index (area under the curve/minimum inhibitory concentration) was associated with the outcome of anti-cryptococcal therapy. Interestingly, the maximum concentration of fluconazole in the brain was lower than the MIC for both strains. In addition, the treatment of mice infected with the resistant strain was ineffective even when high doses of fluconazole were used or when amphotericin B was tested, confirming the cross-resistance between these drugs. Altogether, our novel data provide the correlation of PK/PD parameters with antifungal therapy during cryptococcosis caused by resistant C. gattii.


Asunto(s)
Antifúngicos , Criptococosis , Cryptococcus gattii , Farmacorresistencia Fúngica , Fluconazol , Anfotericina B/uso terapéutico , Animales , Antifúngicos/sangre , Antifúngicos/farmacocinética , Antifúngicos/uso terapéutico , Encéfalo/metabolismo , Encéfalo/microbiología , Cromatografía Liquida , Recuento de Colonia Microbiana , Criptococosis/tratamiento farmacológico , Criptococosis/metabolismo , Criptococosis/microbiología , Cryptococcus gattii/efectos de los fármacos , Cryptococcus gattii/crecimiento & desarrollo , Cryptococcus gattii/aislamiento & purificación , Modelos Animales de Enfermedad , Fluconazol/sangre , Fluconazol/farmacocinética , Fluconazol/uso terapéutico , Pulmón/metabolismo , Pulmón/microbiología , Masculino , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Modelos Biológicos , Espectrometría de Masa por Ionización de Electrospray
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA